Home / Biotechnology / Pharmacogenomics Market By Technology (Microarray, Sequencing, Polymerase Chain Reaction), By Application (Oncology, Cardiology, Pain Management, Neurological Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

Pharmacogenomics Market By Technology (Microarray, Sequencing, Polymerase Chain Reaction), By Application (Oncology, Cardiology, Pain Management, Neurological Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2024

Published: Feb 2017 | Report Code: 58357-02-17

Pharmacogenomics refers to the study of the human genetic make-up and corresponding tailoring of the drug treatment. Each individual response to the drug varies according to the genetic composition. To address such variations, it is necessary to study how the drug processing is affected by the genes. Precise genetic testing helps in determining targeted drug therapies and streamline the treatment protocol to improve therapeutic results. Pharmacogenomics has various therapeutic applications such as oncology, cardiology, pain management, neurological disorder, etc. Thus, through further advancements in this field, the goal is to shift towards preventing, rather than reacting; therefore, optimizing drug therapy, enhancing drug safety, increasing patient compliance and further reducing healthcare cost.

The report titled “Global Pharmacogenomics Market - Growth, Future Prospects and Competitive Analysis, 2016–2024” offers strategic insights into the overall global pharmacogenomics market along with the market size and estimates for the duration 2014 to 2024. This research study covers in-depth analysis of multiple market segments based on type of technology, application and geographical distribution. The technology types studied for analyzing the overall pharmacogenomics market is majorly segmented into microarray, sequencing, polymerase chain reaction, and other technologies. Based on applications the pharmacogenomics market is majorly segmented into oncology, cardiology, pain management, neurological disorders and others.

Geographically, the Global Pharmacogenomics market is studied for the following regional markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Mexico
    • Brazil
    • Rest of LATAM
  • Middle East and Africa

In order to help strategic decision makers, the report also includes competitive profiling of the leading players in the global pharmacogenomics market, attractive investment proposition market positioning of key manufacturers sections. Market size and forecast for these regional and country level markets are presented in this study for the period 2014-2024. Market growth rates for the forecast period 2016-2024 are also included in this report, considering 2015 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global pharmacogenomics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the pharmacogenomics market. This report concludes with company profiles section that highlights major information about the key players engaged in global pharmacogenomics market.

Pharmacogenomics Market

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Pharmacogenomics Market Portraiture
2.2 Global Pharmacogenomics Market Share, by Technology type, 2015 (US$ Mn)
2.3 Global Pharmacogenomics Market Share, by Application type, 2015 (US$ Mn)
2.4 Global Pharmacogenomics Market, by Geography, 2015 (Value %)

Chapter 3 Global Pharmacogenomics Market Analysis
3.1 Global Pharmacogenomics Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Market Drivers
3.3.1.1 Rise in investment in research and development
3.3.1.2 Advancement in technology pharmacogenomics engineering to create in vivo environment
3.3.2 Challenges
3.3.2.1 Lack of consistency in pharmacogenomics products
3.3.3 Opportunities
3.3.3.1 Focus on regenerative medicine
3.3.3.2 Increased awareness of organ transplantation
3.4 Attractive Investment Proposition, 2015
3.5 Market Positioning of Key Players in Pharmacogenomics

Chapter 4 Global Pharmacogenomics Market Analysis, by Technology Type, 2014-2024 (US$ Mn)
4.1 Introduction
4.2 Microarray
4.3 Sequencing
4.3.1 Sanger Sequencing
4.3.2 Pyrosequencing
4.3.3 Next-Generation Sequencing
4.4 Polymerase Chain Reaction
4.5 Other Technologies
4.5.1 Mass Spectrometry
4.5.2 Electrophoresis

Chapter 5 Global Pharmacogenomics Market Analysis, by Application Type, 2014-2024 (US$ Mn)
5.1 Introduction
5.2 Oncology
5.3 Cardiology
5.4 Pain Management
5.5 Neurological Disorders
5.6 Other Applications

Chapter 6 Global Pharmacogenomics Market, by Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.3 Europe (U.K., Germany & Rest of Europe)
6.4 Asia Pacific (China, Japan, and Rest of APAC)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.6 Middle East and Africa (UAE, Saudi Arabia, South Africa)

Chapter 7 Company Profiles
7.1 Abbott Laboratories, Inc.
7.2 Affymetrix, Inc.
7.3 AstraZeneca plc
7.4 Assurex Health
7.5 Bayer AG
7.6 GeneDX
7.7 F. Hoffmann-La Roche Ltd.
7.8 Illumina, Inc
7.9 Myriad Genetics, Inc
7.10 Merck & Co
7.11 GE Healthcare
7.12 GlaxoSmithKline
7.13 Johnson & Johnson
7.14 Pfizer, Inc.
7.15 Pathway Genomics
7.16 Qiagen, Inc.
7.17 Teva Pharmaceutical Industries Ltd
7.18 Thermo Fisher Scientific
7.19 Transgenomic, Inc.
7.20 Other Notable Players

Note:

  • Profiles of specific players, if required, shall be added to the report upon request

List of Tables :

TABLE 1 Global Pharmacogenomics Market, By Technology Type 2014-2024 (US$ Mn)
TABLE 2 Global Sequencing Market, By Technology Type 2014-2024 (US$ Mn)
TABLE 3 Global Pharmacogenomics Market, By Application Type 2014-2024 (US$ Mn)
TABLE 4 Global Pharmacogenomics Market, by Geography, 2014 – 2024 (US$ Mn)
TABLE 5 North America Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 6 Europe Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 7 Asia-Pacific Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 8 Latin America Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 9 Middle East and Africa Pharmacogenomics Market, by Country, 2014 – 2024 (US$ Mn)
TABLE 10 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 11 Affymetrix, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 12 AstraZeneca plc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 13 Assurex Health: Company Snapshot (Business Description; Financial Performance; Product Position Portfolio; News Coverage)
TABLE 14 C Bayer AG: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 15 GeneDX: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 C B F. Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Illumina, Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 18 Myriad Genetics, Inc: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 19 Merck & Co: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 20 GE Healthcare: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 21 GlaxoSmithKline: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 22 Johnson & Johnson: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 23 Pfizer, Inc. : Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 24 Pathway Genomics : Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 25 Qiagen, Inc.: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 26 Teva Pharmaceutical Industries Ltd: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 27 Thermo Fisher Scientific: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)
TABLE 28 Transgenomic, Inc.s: Company Snapshot (Business Description; Financial Performance; Product Portfolio; News Coverage)

List of Figures :

FIG. 1 Global Pharmacogenomics Market: Research Methodology
FIG. 2 Global Pharmacogenomics Market Share, by Technology type, 2015 (US$ Mn)
FIG. 3 Global Pharmacogenomics Market Share, by Application type, 2015 (US$ Mn)
FIG. 4 Global Pharmacogenomics Market, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition: Global Pharmacogenomics Market, by Geography
FIG. 6 Market Positioning of Key Players in Pharmacogenomics
FIG. 7 Global Microarray Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 8 Global Sanger Sequencing Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 9 Global Pyrosequencing Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 10 Global Next-Generation Sequencing Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 11 Global Polymerase Chain Reaction sMarket in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 12 Global Other Technologies Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 13 Global Mass Spectrometry Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 14 Global Electrophoresis Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 15 Global Oncology Market in Pharmacogenomics, 2014 – 2024 (US$ Mn )
FIG. 16 Global Cardiology Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 17 Global Pain Management Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 18 Global Neurological Disorders Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)
FIG. 19 Global Other Application Market in Pharmacogenomics, 2014 – 2024 (US$ Mn)

Based on the type of Therapeutic application, the global pharmacogenomics market is segmented as follows:

  • Oncology
  • Cardiology
  • Psychiatry
  • Infectious Diseases
  • Pain Management
  • Neurological Disorders
  • Others

Oncology, psychiatry, and infectious diseases are the three leading therapeutic areas that are benefited from pharmacogenomics. With help of pharmacogenomics studies, there is a paradigm shift in respective treatments, focusing on the personalized therapeutics. Oncology dominates the therapeutic applications in the pharmacogenomics market. Pharmacogenomics studies help cancer treatment by making selective decision of the drug, by anticipating the drug response, efficacy, safety profile, toxicity within chemotherapeutic agents and targeted immune biologics agents. Since the past few years, there has been an increase in clinical adoption of psychiatric pharmacogenomics testing. Due to cost effectiveness of this testing, it would be of help in near future to select psychotropic drug, its dosing and avoid further side effects according to the need of the patient. Pharmacogenomics is being used to study the genome of both the host and pathogen. The study of pathogen genome used in identification of the antigen, determine microbial resistance and further help in designing vaccine. Therefore, pharmacogenomics has the potential to revolutionize the prevention, diagnosis, and treatment of infectious diseases.

Pharmacogenomics Market

Based on the type of technology, the global pharmacogenomics Market is segmented as follows:

  • Microarray
  • Sequencing
    • Sanger Sequencing
    • Pyrosequencing
    • Next-Generation Sequencing
  • Polymerase Chain Reaction
  • Other Technologies
    • Mass Spectrometry
    • Electrophoresis

DNA sequencing is technique used to determine the sequence of nucleotide (Adenine, Guanine, Cytosine, and Thymine) in a particular region of DNA. With technological advancement, sequencing has gone through three generation which includes: First generation - Sanger sequencing and Gilbert sequencing; Second generation - pryrosequencing; Next generation – Illumina (Solexa). It has ability to read DNA template in real time without amplification providing accurate and precise sequencing data. Thus next generation sequencing dominates the pharmacogenomics market and is anticipated to further grow in the forecast period. PCR is another technology widely used to replicate DNA sequence in short duration of time. Real time PCR helps to provide comprehensive content and also helps in pharmacogenomics studies to give quick accurate result at lower cost. Microarray is another fast growing technology in the field of molecular biology and genetics. DNA microarray technique is used in pharmacogenomics to search and validate new therapeutic targets, to understand the metabolic pathways, mechanism of action, and unwanted secondary effects. Mass spectrometry is a high throughput technology used for detection of genotyping, thus help in understanding how the drug interact with the patient. It is a quick process and less expensive and is used for of drug monitoring, thus its market is anticipated to grow in future.

Pharmacogenomics Market

For the purpose of this study, the global pharmacogenomics market is geographically categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Pharmacogenomics Market

At present, North America dominates the pharmacogenomics market followed by Europe. In developed countries, with advancement in research and development, the goal is to shift towards preventing, rather than reacting, optimizing the drug therapy, enhancing drug safety, increasing patient compliance and further reducing healthcare cost. Personalized medicine emphasize on the paradigm shift in medicine from reaction to prevention. Asia Pacific is expected to be the most attractive regional market in the global pharmacogenomics market and promises extensive growth during the forecast period. The driving factors for the market are presence of extensive and evolved healthcare infrastructure, increasing preference for better, cost effective and personalized therapeutics for various diseases and infections.  There is being rising R&D infrastructure and government initiatives making the region vulnerable for healthcare investments and also rising research centers for personalized treatment due to extensive population and various infections prevalent in the region.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients